Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis
Cells · 2023
DOI: 10.3390/cells12242855 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Sulaiman Mohammed Alnasser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for cancer patients undergoing high-dose chemotherapy (HDC). When chemotherapy is used at very high doses to eradicate all cancer cells from aggressive tumors, blood-forming cells and leukocytes are either completely or partially destroyed. Autologous stem cell transplantation (ASCT) is necessary for patients in those circumstances. The patients who undergo autologous transplants receive their own stem cells (SCs). The transplanted stem cells first come into contact with the bone marrow and then undergo engraftment, before differentiating into blood cells. ASCT is one of the most significant and innovative strategies for treating diseases. Here we focus on the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, and AL amyloidosis, using ASCT. This review provides a comprehensive picture of the effectiveness and the safety of ASCT as a therapeutic approach for these diseases, based on the currently available evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
- Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
ORCID-Profile: Sulaiman Mohammed Alnasser
Zitieren
APA
Alnasser, S. M., Alharbi, K. S., Almutairy, A. F., Almutairi, S. M., & Alolayan, A. M. (2023). Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis. Cells. https://doi.org/10.3390/cells12242855
Vancouver
Alnasser SM, Alharbi KS, Almutairy AF, Almutairi SM, Alolayan AM. Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis. Cells. 2023. doi:10.3390/cells12242855
BibTeX
@article{Alnasser2023,
author = {Alnasser, Sulaiman Mohammed and Alharbi, Khalid Saad and Almutairy, Ali F and Almutairi, Sulaiman Mohammed and Alolayan, Abdulmalik Mohammed},
title = {Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12242855}
}
EUVIMED